On September 30, 2020, the Third Circuit reversed a decision by the Eastern District of Pennsylvania ordering AbbieVie, Inc. (“AbbieVie”) and Besins Healthcare Inc. (“Besins”) to pay $448 million in disgorgement of ill-gotten profits for allegedly filing sham patent lawsuits to stifle competition. AbbieVie and Besins had filed patent infringement lawsuits against two developers of generic alternatives to its brand-name testosterone gel product AndroGel. The FTC sued AbbieVie and Besins in 2014 alleging that the patent suits were baseless and brought for no other ...
Blog Editors
Recent Updates
- Navigating Regulatory Challenges in the Dietary Supplement Industry: Insights on NJ Assembly Bill No. 1848
- Quashing an Out-of-State Subpoena: No Easy Task
- The Sleeping Giant: New York’s Commercial Division Expert Disclosure Rules
- Commission Commitments: Massachusetts Appeals Court Upholds Obligation to Continue Paying Commission for the Life of the Underlying Customer Relationship
- A Win for Out-of-Network Providers